The Science Behind ALZAI

ALZAI delivers risk-assessment of being diagnosed with Alzheimer's Disease up to 10 years out. ALZAI uses pre-existing common patient data and patented AI technology enabling risk- profiling by year.

The Research Behind ALZAI

ALZAI is the first AI-driven Alzheimer’s Disease risk screening platform, enabling disease prevention and early disease diagnosis to improve patient outcomes.

ALZAI uses low-cost, non-invasive, pre-existing biomarker data present nearly all Electronic Medical Records of the relevant age demographic. Our AI algorithms are trained on longitudinal data of over 500,000 diverse individuals from the world-renown Israeli public healthcare provider, Clalit Healthcare Services. ALZAI demonstrated consistently over 80% sensitivity in predicting Alzheimers disease diagnoses from non-symptomatic individuals, allowing individuals and healthcare provider to act on risk profiles up to a decade in advance of onset.

The History of ALZAI

2021

Dr. Amir Glik of Clalit Health Services began ideation of a solution to address the critical unmet need of pre-symptomatic risk-screening for Alzheimer's Disease.

2022

Along with AI & ML leaders from Ariel University, the team gained access to longitudinal healthcare data from 500,000 individuals enrolled with Clalit Health Service with 20+ years of clinical history. Research and algorithm refinement commenced. The system was refined and 3 large scale trials were conducted proving efficacy.

2024

The processes and suite of AI algorithms was patent protected. The value of ALZAI’s solution for Alzheimer’s Disease Screening was recognized and the IP was licensed to a founder's team of seasoned medical technology business, clinical and AI leaders,. ALZAI Health Corp was founded and commercial interest was established with the clinical research community, healthcare providers, and payors.

2025

ALZAI released it’s first web-based screening tool for commercial clinical research and payor/provider applications. The future of ALZAI is bright as we address the major unmet need of risk screening for Alzheimer’s Disease.